SSTR2/SS2R recombinant proteins and antibodies

Somatostatin receptor 2 (SSTR2), also called SS2R or SRIF-1, is a G protein-coupled receptor belonging to the somatostatin receptor family, widely expressed in the central nervous system, endocrine system, and certain tumor cells. SSTR2 primarily regulates various physiological processes by binding to somatostatin, such as inhibiting the secretion of growth hormone, reducing insulin secretion, regulating gastrointestinal function, and affecting neurotransmitter release. Its role in endocrine tumors, neuroendocrine tumors, and pituitary tumors has gained significant attention, making SSTR2 an important target in cancer therapy.

Agonists of SSTR2, such as octreotide and lanreotide, are already used clinically to treat neuroendocrine tumors and other endocrine disorders. These drugs activate the SSTR2 receptor, inhibiting tumor cell proliferation, reducing hormone secretion by tumors, and alleviating tumor-related symptoms. However, the efficacy of existing drugs is still somewhat limited, particularly in treating certain types of neuroendocrine tumors, where issues such as drug resistance and treatment efficacy remain significant. As a result, researchers are working to develop new and more selective SSTR2 agonists and other related therapies. Currently, several biopharmaceutical companies are developing drugs based on the SSTR2 target. Companies like Ipsen and Novartis have already launched SSTR2 agonists for treating neuroendocrine tumors and pituitary adenomas. At the same time, radiolabeled drugs targeting SSTR2 are also under active development. These radiopharmaceuticals are particularly promising in tumor-targeted therapy, where radioactive isotopes can be delivered directly to tumor cells via binding to the SSTR2 receptor, thereby enhancing therapeutic efficacy and minimizing damage to normal tissues. Additionally, other companies are exploring novel treatment combinations that combine SSTR2 agonists with immunotherapy, aiming to enhance the effectiveness of cancer immunotherapy. With ongoing research into the SSTR2 target, it is expected that more innovative drugs will enter clinical trials, offering more treatment options for neuroendocrine tumors and other related diseases.

To assist in the development of SSTR2 targeted drugs, DIMA BIOTECH can now provide a series of spot products targeting SSTR2, including SSTR2 recombinant proteins, SSTR2 full-length membrane proteins, anti-SSTR2 monoclonal antibodies and biosimilar reference antibodies. At the same time, we can also provide systematic services, including protein/antibody customization services, antibody humanization, antibody affinity maturation, stable cell lines, etc. In addition, we have established a B cell seed bank targeting SSTR2, which can screen out the lead antibody molecules required by customers in just 20 days.